A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

• Status: Completed
• Trial end date: 2018-01-08
• Target enrollment: 0
• Participant gender: All

Summary

The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• primary IgA nephropathy

• age 18-75 years

• proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB

• eGFR>30ml/min/1.73m2

Exclusion Criteria:

• immune suppressive agent in recent one years

• crescent glomerulonephritis, might use immune suppressive agent

• chronic hepatic disease

• myocardial infarction

• malignant hypertension

• stroke

• malignant tumor

• retinopathy

• other contraindication of Hydroxychloroquine

• pregnancy and breastfeeding women

• life expectancy for less than 6 months

• in other clinical trials

• not suitable for the study judged by investigator